Nonalcoholic fatty liver disease (NAFLD) is the liver manifestation of metabolic syndrome in which obesity and resistance to the insulin action are the hallmark. Fat accumulation in the liver produces inflammation and chronic liver damage, known as non-alcoholic steatohepatitis (NASH). Nowadays, the best strategy to treat NAFLD and NASH is weight loss. Surgical procedures to treat obesity (bariatric surgery) have shown good results to reduce fat accumulation and even improve other obesity-related conditions. However, neither the benefits nor the harms of bariatric surgery in NASH have been assessed in any systematic review or meta-analysis of randomised clinical trials. The present Cochrane review attempted to evaluate the benefits and risks of bariatric surgery for NASH in obese patients, but as no randomised clinical trials fulfilling the inclusion criteria of the review protocol were found, the review was not able to address the pre-specified in the protocol aims. Prospective and retrospective cohort studies reported on beneficial effects on steatosis and inflammation, with potential increase of liver fibrosis, but the studies were too heterogenous and with a small number of patients. Hence, the data, which the latter studies contained, are with a high risk of bias, and a reliable summary of their data cannot be achieved. Due to the absence of trials, well-designed randomised trials to assess bariatric surgery as a safe and effective treatment of NASH are required.
阅读完整摘要
Nonalcoholic fatty liver disease (NAFLD) is increasingly recognised as a condition associated with overweight or obesity that may progress to end-stage liver disease. NAFLD histology resembles alcohol-induced liver injury, but occurs in patients with no history of alcohol abuse. NAFLD has a broad spectrum of clinical and histological manifestations, ranging from simple fatty liver to hepatic steatosis with inflammation, advanced fibrosis, and cirrhosis. The inflammatory stage is known as non-alcoholic steatohepatitis (NASH). Recent reports indicate that weight loss induced by bariatric procedures could be beneficial for NASH treatment.
研究目的
To assess the benefits and harms of bariatric surgery for NASH in obese patients.
检索策略
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded to October 2009.
纳入排除标准
All randomised clinical trials evaluating any bariatric procedure versus no intervention, placebo (sham procedure), or other interventions in patients with NASH regardless of publication status, number of patients randomised, language, or blinding. Quasi-randomised clinical studies were to be considered for the review if no randomised clinical trials were identified. If included, their bias towards positive findings was to be considered.
资料收集与分析
We extracted data in duplicate, and we planned to analyse the data by intention-to-treat.
主要结果
We could not find any randomised clinical trials or quasi-randomised clinical studies that fulfilled the inclusion criteria. Our search resulted in twenty-one prospective or retrospective cohort studies, in which improvement on steatosis or inflammation scores was reported. However, four studies also described some deterioration in the degree of fibrosis.
作者结论
The lack of randomised clinical trials and quasi-randomised clinical studies precludes us to assess the benefits and harms of bariatric surgery as a therapeutic approach for patients with NASH. Limitations of all other studies with inferior design did not allow us to draw any unbiased conclusion on bariatric surgery for treatment of NASH.
